These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 25360799)

  • 1. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
    Mediwala SN; Sun H; Szafran AT; Hartig SM; Sonpavde G; Hayes TG; Thiagarajan P; Mancini MA; Marcelli M
    Prostate; 2013 Feb; 73(3):267-77. PubMed ID: 22821817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
    Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
    J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
    Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
    Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
    Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
    Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
    Deep G; Oberlies NH; Kroll DJ; Agarwal R
    Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
    Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.